Doravirine

Not to be confused with drotaverine or darunavir.

Doravirine, sold under the brand name Pifeltro, is a non-nucleoside reverse transcriptase inhibitor medication developed by Merck & Co. for use in the treatment of HIV/AIDS.

Doravirine

Clinical data
Trade names	Pifeltro
Other names	MK-1439
AHFS/Drugs.com	Monograph
MedlinePlus	a618048
License data	US DailyMed: Doravirine
Routes of administration	By mouth[1][2]
ATC code	J05AG06 (WHO)
Legal status
Legal status	AU: S4 (Prescription only) CA: ℞-only[3][4] UK: POM (Prescription only)[5] US: ℞-only[1] EU: Rx-only[6]
Identifiers
IUPAC name 3-Chloro-5-({1-[(4-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)methyl]-2-oxo-4-(trifluoromethyl)-1,2-dihydro-3-pyridinyl}oxy)benzonitrile
CAS Number	1338225-97-0
PubChem CID	58460047
DrugBank	DB12301
ChemSpider	28424197
UNII	913P6LK81M
KEGG	D10624
ChEMBL	ChEMBL2364608
PDB ligand	2KW (PDBe, RCSB PDB)
CompTox Dashboard (EPA)	DTXSID30158386
ECHA InfoCard	100.234.454
Chemical and physical data
Formula	C17H11ClF3N5O3
Molar mass	425.75 g·mol−1
3D model (JSmol)	Interactive image
SMILES Cn1c(n[nH]c1=O)Cn2ccc(c(c2=O)Oc3cc(cc(c3)Cl)C#N)C(F)(F)F
InChI InChI=1S/C17H11ClF3N5O3/c1-25-13(23-24-16(25)28)8-26-3-2-12(17(19,20)21)14(15(26)27)29-11-5-9(7-22)4-10(18)6-11/h2-6H,8H2,1H3,(H,24,28) Key:ZIAOVIPSKUPPQW-UHFFFAOYSA-N

Doravirine was approved for medical use in the United States in August 2018.^[7]

Doravirine is available in fixed-dose combinations with other HIV drugs such as doravirine/lamivudine/tenofovir (sold under the brand name Delstrigo).^[8]